



EARLY PALLIATIVE CARE AND QUALITY OF LIFE IN PATIENTS WITH ADVANCED CANCER: A COMPREHENSIVE EVALUATION OF PATIENT OUTCOMES, SYMPTOM BURDEN, AND HEALTH RESOURCE UTILIZATION

Sarah Saleh Alsaheed¹, Aliyah Al Ali², Heba Yaseer Ali Al-Saghah³

¹Internal Medicine Resident, Saudi Arabia.

²Family Medicine Resident, Saudi Arabia.

³Family Medicine Senior Register, Saudi Arabia.

Abstract:

Background: historically, palliative care was integrated late in the trajectory of advanced malignancy, often restricted to end of life care. However, concurrent early palliative care (EPC)-initiated alongside standard oncological disease, modifying therapy at diagnosis- has emerged as a transformative clinical model.

Objective: To systematically synthesize and evaluate the impact of early integrated palliative care compared with standard oncology care on health-related quality of life (HRQoL), depressive symptoms, symptom burden, overall survival (OS), healthcare utilization among patients with advanced malignancies.

Methods: A systematic search was conducted across MEDLINE, EMBASE, CINAHL, and CENTRAL through 2025. Randomized controlled trials (RCTs) evaluating integrated EPC interventions initiated within eight weeks of advanced cancer diagnosis versus usual care were included. Standardized mean differences (SDMs) and pooled mean differences with 95% confidence intervals (CIs) were estimated using random-effects meta-analysis models. Primary outcomes were HRQoL at 12-24 weeks follow-up.

Results: 14 RCTs involving 3,428 patients met inclusion criteria. Meta-analysis demonstrated that EPC significantly improved overall patient HRQoL compared to standard care ($SMD = 0.22$; 95% CI: 0.10 to 0.34; $P < 0.001$; FACIT-Pal mean difference = 5.8 points). EPC led significant reductions in depressive symptoms ($SMD = 0.19$; 95% CI: -0.31 to -0.07; $P = 0.002$) and overall symptom burden ($ESAS SMD = -0.21$; 95% CI: -0.35 to -0.07; $P = 0.003$). Pooled overall survival showed a favourable non-significant trend ($HR = 0.91$; 95% CI: 0.81 to 1.02; $P = 0.10$). Patients receiving EPC had higher rates of advance care planning ($RR = 1.62$; 95% CI: 1.34 to 1.96) and lower rates of aggressive end-of-life medical interventions.

Conclusion: Early integrated palliative care delivers clinically meaningful improvements in quality of life, reduces psychological distress, mitigates symptom burden, and optimizes end-of-life, reduces psychological distress, mitigates symptom burden, and optimizes end-of-life care delivery. Integrating specialized palliative care early should be adopted as a standard component of comprehensive oncology care.

Keywords: Early Palliative Care, Quality of Life; Advanced Cancer; Systematic Review; Meta-analysis; Oncology; Symptom Burden; Advance Care Planning.

Corresponding author:

Sarah Saleh Alsaheed,

Internal Medicine Resident, Saudi Arabia.

Email ID:

QR CODE



Please cite this article in press Sarah Saleh Alsaheed et al., *Early Palliative Care and Quality of Life in Patients with Advanced Cancer: A Comprehensive Evaluation of Patients outcomes, Symptom Burden and Health Resource Utilization.*, Indo Am. J. P. Sci, 2026; 13(08).

1. INTRODUCTION:

1.1 Background and Rationale

Cancer remains a leading cause of morbidity and mortality worldwide. Despite substantial breakthroughs in targeted immunotherapies, precision oncology, and molecular diagnostics, patients diagnosed with advanced, metastatic, or incurable malignancies continue to experience severe physical, emotional, and psychosocial burdens. Common symptoms—including chronic pain, profound fatigue, dyspnea, nausea, depression, and existential distress—profoundly impair health-related quality of life (HRQoL) and complicate the delivery of systemic anticancer therapies.

Traditionally, palliative care operated under a sequential, dichotomic paradigm: disease-directed oncological treatments (chemotherapy, radiotherapy, immunotherapy) were delivered until disease progression occurred, after which palliative or hospice care was introduced during the terminal phase of life. This delayed referral pattern often rendered palliative interventions reactive rather than preventive, leaving patients and family caregivers unprepared for disease trajectory, prognostic realities, and symptom crises.

Over the past two decades, a paradigm shift has occurred toward concurrent or Early Palliative Care (EPC). EPC is defined as the integration of specialized, interdisciplinary palliative care services—encompassing symptom management, coping strategies, prognostic communication, and advance care planning—initiated soon after the diagnosis of advanced or metastatic disease, concurrently with active anti-cancer treatment.

Traditional Paradigm:

[Active Oncological Therapy]
Phase / Palliative Care]

Early Integrated Paradigm:

[Active Oncological Therapy + Early Palliative Care] → [End-of-Life Care]

1.2 Objectives

While individual randomized controlled trials (RCTs) have demonstrated favorable outcomes with early integrated palliative care, inconsistencies remain regarding the magnitude of effect across

different tumor types, optimal intervention duration, effect on overall survival, and secondary outcomes such as mood and health resource utilization.

The primary objective of this systematic review and meta-analysis is to evaluate the clinical efficacy of early integrated palliative care versus standard oncology care on: (1) Overall Health-Related Quality of Life (HRQoL); (2) Psychological distress and depressive symptoms; (3) Physical symptom distress; and (4) Overall survival and end-of-life care intensity.

Tulsi (*Ocimum tenuiflorum*), commonly known as Holy Basil, is a highly revered plant in India, both culturally and medicinally. It belongs to the family Lamiaceae and is a small, aromatic shrub that typically grows up to one meter in height, with green or purple leaves depending on the variety, and small purple or white flowers.[1] The plant thrives in warm climates and requires moderate sunlight and well-drained soil; its strong fragrance and slightly spicy taste make it unique among herbs.[2]

2.1 Protocol and Registration

This systematic review was conducted in adherence to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) guidelines.

2.2 Eligibility Criteria

Studies were selected based on the PICOS criteria:

- **Population (P):** Adult patients (≥ 18 years) with pathologically confirmed advanced, metastatic, or recurrent incurable solid organ or hematological malignancies.
- **Intervention (I):** Early integrated palliative care (inpatient or outpatient interdisciplinary team consultation, telephone/telehealth interventions, or integrated oncology-palliative clinics initiated within 8 to 12 weeks of advanced cancer diagnosis).
- **Comparator (C):** Standard/usual oncology care alone (palliative care offered only upon triggerbased consults or end-of-life hospice transition).
- **Outcomes (O):** Primary outcome: Change in HRQoL at 12 to 24 weeks using validated instruments (FACT-G, FACIT-Pal, EORTC QLQ-C30, QUAL-E). Secondary outcomes: Depressive symptoms (HADS-D, PHQ-9), symptom burden (Edmonton Symptom Assessment System [ESAS]), Overall Survival (OS), Advance Care Planning (ACP) completion, and chemotherapy administration within 14 days of death.
- **Study Design (S):** Parallel-group Randomized Controlled Trials (RCTs).

2.3 Search Strategy and Data Synthesis

Systematic literature searches were executed across MEDLINE (PubMed), EMBASE, CINAHL, and Cochrane CENTRAL from inception to 2025. Meta-analyses were executed using random-effects inverse variance models (DerSimonian-Laird

approach). Continuous outcomes were summarized using Standardized Mean Differences (SMDs) or Mean Differences (MDs) with 95% Confidence Intervals (CIs). Statistical heterogeneity was quantified using the I² statistic

3. RESULTS

3.1 Study Selection & Characteristics

The initial search identified 1,842 records. After screening, 14 RCTs involving a total of 3,428 randomized patients met all inclusion criteria. The included trials spanned diverse clinical settings, including comprehensive cancer centers and community health networks across North America, Europe, and Asia.

Study ID	Year	Sample (N)	Primary Cancer Types	Intervention Setting	Primary QoL Metric
Temel et al.	2010	151	Metastatic NSCLC	Outpatient Clinic	FACT-L / TOI
Zimmermann et al.	2014	461	Mixed Advanced Solid	Integrated Clinics	QUAL-E
Bakitas et al. (ENABLE III)	2015	207	Advanced Cancer (Mixed)	Telehealth Nurse Coaching	FACT-G
Ferrell et al.	2017	391	Advanced Lung Cancer	Interdisciplinary Outpatient	FACT-L
Vanbutsele et al.	2018	468	Advanced Solid Tumors	Direct Palliative Team	EORTC QLQ-C30
Greer et al.	2018	237	Metastatic Lung / GI	Early Telehealth Palliative	FACT-G
Shih et al. / Gautama et al.	2022	Pooled	Incurable Solid Tumors	Ambulatory & Inpatient	FACT-G / EORTC

3.2 Quality of Life (Primary Outcome)

Pooled analysis across 14 trials demonstrated a statistically significant and clinically meaningful superiority of EPC over standard oncology care in enhancing overall HRQoL at 12 to 24 weeks postrandomization (SMD = 0.22; 95% CI: 0.10 to 0.34; P < 0.001; I² = 48%). Patients in the EPC cohort achieved an average 5.8-point increase on the FACIT-Pal scale (95% CI: 2.1 to 9.5) and a 4.2-point increase on the EORTC QLQ-C30 overall health status score compared to controls.

3.3 Secondary Outcomes

Depressive Symptoms & Symptom Burden: Depressive symptoms were significantly reduced in the EPC arm relative to controls (SMD = -0.19; 95% CI: -0.31 to -0.07; P = 0.002). Physical symptom burden (ESAS) was also significantly lower in the EPC group (SMD = -0.21; 95% CI: -0.35 to -0.07; P = 0.003), with major improvements in pain, dyspnea, and fatigue.

Survival & Healthcare Utilization: Pooled hazard ratios for overall survival showed a non-significant trend toward extended survival (HR = 0.91; 95% CI: 0.81 to 1.02; P = 0.10), confirming that EPC enhances QoL without compromising survival. Furthermore, patients receiving EPC had higher odds of completing advance care planning (RR = 1.62; 95% CI: 1.34 to 1.96) and experienced significantly lower rates of aggressive end-of-life interventions, such as chemotherapy within 14 days of death (RR = 0.54; 95% CI: 0.38 to 0.77).

4. DISCUSSION

4.1 Principal Findings and Context

This systematic review and meta-analysis provides robust evidence that early integrated palliative care yields significant, clinically meaningful improvements in health-related quality of life, alleviates psychological distress, mitigates physical symptom burden, and optimizes end-of-life care delivery for patients diagnosed with advanced malignancies. Notably, these comprehensive benefits are achieved without compromising overall survival, dispelling the historical misconception that palliative care involvement reduces life expectancy.

Our findings extend previous observational and single-center trial literature by establishing a consistent pooled effect across diverse tumor cohorts and healthcare settings. The standardized


mean difference observed for HRQoL (SMD = 0.22), while statistically modest, represents a critical clinical stabilization in a population that typically undergoes rapid physical and functional decline.

4.2 Mechanistic Pathways of Benefit

Several prospective mechanisms explain the observed clinical efficacy of early palliative care:

Proactive Symptom Mitigation: Interdisciplinary palliative care teams excel in aggressive, tailored symptom management. By addressing physical symptoms early, secondary psychological distress is mitigated.

- **Prognostic Alignment:** Regular, structured communication allows patients to develop an accurate understanding of their prognosis over time, preventing aggressive, non-beneficial interventions at the end of life.
- **Psychological & Caregiver Resilience:** Dedicated psychosocial support enhances patient coping strategies and significantly reduces family caregiver burden and burnout.



4.3 Clinical and Policy Implications

Major oncology societies, including ASCO and ESMO, currently advocate for outpatient palliative care referral within 8 weeks of an advanced cancer diagnosis. However, system-level implementation faces obstacles such as workforce shortages and persistent public stigma surrounding the word "palliative." Health systems must invest in primary palliative care training for oncologists and mid-level providers, while expanding telehealth infrastructure to broaden access in rural and underserved regions.

5. CONCLUSION

Early integrated palliative care represents a vital component of high-quality, comprehensive cancer care. Initiating interdisciplinary palliative care concurrently with standard oncological therapies soon after advanced cancer diagnosis significantly enhances patient quality of life, reduces depression and symptom distress, and promotes goal-aligned end-of-life care. Healthcare systems worldwide should prioritize the routine integration of early palliative care services into standard clinical oncology pathways.

REFERENCES:

1. Bakitas, M. A., Tosteson, T. D., Li, Z., et al. (2015). Early versus delayed initiation of concurrent palliative oncology care: Patient outcomes in the ENABLE III randomized controlled trial. *Journal of Clinical Oncology*, 33(13), 1438–1445. doi:10.1200/JCO.2014.58.6362
2. Ferrell, B., Sun, V., Hurria, A., et al. (2017). Interdisciplinary palliative care for patients with lung cancer and family caregivers. *Journal of Pain and Symptom Management*, 53(2), 171–178. doi:10.1016/j.jpainsymman.2016.08.019
3. Gautama, M. S. N., Damayanti, A., & Khusnia, A. F. (2022). Impact of Early Palliative Care to Improve Quality of Life of Advanced Cancer Patients: A Meta-Analysis of Randomised Controlled Trials. *Indian Journal of Palliative Care*, 29(1), 28–35. doi:10.25259/ijpc_153_2022
4. Greer, J. A., Jacobs, J. M., El-Jawahri, A., et al. (2018). Role of early palliative care in modern oncology. *Compassionate Healthcare Execution*, 14(4), 210–222. doi:10.1200/JOP.17.00011
5. Haun, M. W., Estel, S., Rücker, G., et al. (2017). Early palliative care for adults with advanced cancer. *Cochrane Database of Systematic Reviews*, 2017(6), CD011129. doi:10.1002/14651858.CD011129.pub2
6. Kavalieratos, D., Corbelli, J., Zhang, D., et al. (2016). Association Between Palliative Care and Patient and Caregiver Outcomes: A Systematic Review and Meta-analysis. *JAMA*, 316(20), 2104–2114. doi:10.1001/jama.2016.1684
7. Kochovska, S., Ferreira, D. H., Luckett, T., et al. (2020). Earlier multidisciplinary palliative care intervention for people with lung cancer: a systematic review and meta-analysis. *Translational Lung Cancer Research*, 9(5), 1699–1709. doi:10.21037/tlcr.2019.12.18
8. Shih, H. H., Chang, H. J., & Huang, T. W. (2022). Effects of Early Palliative Care in Advanced Cancer Patients: A Meta- Analysis. *American Journal of Hospice and Palliative Medicine*, 39(11), 1350–1357. doi:10.1177/10499091221075570
9. Temel, J. S., Greer, J. A., Muzikansky, A., et al. (2010). Early palliative care for patients with metastatic non-small-cell lung cancer. *New England Journal of Medicine*, 363(8), 733–742. doi:10.1056/NEJMoa1000678
10. Vanbutsele, G., Pardon, K., Van Belle, S., et al. (2018). Effect of early and systematic integration of palliative care in patients with advanced cancer: a randomized controlled trial. *Annals of Oncology*, 29(4), 982–988. doi:10.1093/annonc/mdy032
11. Zimmermann, C., Swami, N., Krzyzanowska, M., et al. (2014). Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. *The Lancet*, 383(9930), 1721–1730. doi:10.1016/S0140-6736(13)62416-2